CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Bought by Truist Financial Corp

Truist Financial Corp raised its position in CRISPR Therapeutics AG (NASDAQ:CRSPGet Rating) by 81.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 5,996 shares of the company’s stock after buying an additional 2,699 shares during the period. Truist Financial Corp’s holdings in CRISPR Therapeutics were worth $392,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of CRSP. HM Payson & Co. boosted its holdings in CRISPR Therapeutics by 500.0% in the 3rd quarter. HM Payson & Co. now owns 480 shares of the company’s stock worth $31,000 after buying an additional 400 shares during the last quarter. Country Trust Bank purchased a new position in CRISPR Therapeutics in the 3rd quarter worth approximately $33,000. International Biotechnology Trust PLC purchased a new position in CRISPR Therapeutics in the 2nd quarter worth approximately $34,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its stake in CRISPR Therapeutics by 159.2% in the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 635 shares of the company’s stock worth $39,000 after purchasing an additional 390 shares in the last quarter. Finally, Wipfli Financial Advisors LLC purchased a new position in CRISPR Therapeutics in the 3rd quarter worth approximately $41,000. 71.51% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Stock Up 1.2 %

Shares of NASDAQ CRSP opened at $51.96 on Wednesday. The firm has a market cap of $4.07 billion, a price-to-earnings ratio of -5.90 and a beta of 1.77. CRISPR Therapeutics AG has a 52-week low of $38.94 and a 52-week high of $86.95. The business’s 50 day moving average is $49.30 and its two-hundred day moving average is $60.55.

CRISPR Therapeutics (NASDAQ:CRSPGet Rating) last posted its quarterly earnings results on Tuesday, November 1st. The company reported ($2.24) EPS for the quarter, topping the consensus estimate of ($2.30) by $0.06. The business had revenue of $0.09 million during the quarter, compared to the consensus estimate of $3.53 million. CRISPR Therapeutics had a negative net margin of 4,831.79% and a negative return on equity of 31.34%. Analysts anticipate that CRISPR Therapeutics AG will post -9.25 EPS for the current fiscal year.

Analyst Ratings Changes

CRSP has been the topic of a number of research reports. Barclays decreased their target price on shares of CRISPR Therapeutics from $88.00 to $61.00 in a research note on Wednesday, November 2nd. Citigroup decreased their target price on shares of CRISPR Therapeutics from $83.00 to $63.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 23rd. EF Hutton Acquisition Co. I initiated coverage on shares of CRISPR Therapeutics in a research report on Thursday, January 5th. They set a “buy” rating and a $75.00 price target on the stock. SVB Leerink lifted their price target on shares of CRISPR Therapeutics from $75.00 to $76.00 and gave the company an “outperform” rating in a research report on Monday, November 7th. Finally, Morgan Stanley initiated coverage on shares of CRISPR Therapeutics in a research report on Tuesday, October 11th. They set an “underweight” rating and a $37.00 price target on the stock. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $98.22.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 25,000 shares of the business’s stock in a transaction on Wednesday, December 28th. The shares were sold at an average price of $40.93, for a total value of $1,023,250.00. Following the completion of the transaction, the chief executive officer now owns 369,111 shares in the company, valued at $15,107,713.23. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 5.30% of the company’s stock.

CRISPR Therapeutics Profile

(Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Read More

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSPGet Rating).

Institutional Ownership by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.